ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1403

MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients

Kristyna Bubova1, Lenka Hasikova2, Katerina Mintalova2, Monika Gregova2, Sarka Forejtova2, Ladislav Senolt3 and Karel Pavelka4, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, 4Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), Magnetic resonance imaging (MRI), spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Sacroiliitis is a main radiographic finding in axial spondyloarthritis (axSpA) – the inflammatory rheumatic disease with a strong genetic background. The aim of this study was to evaluate the presence of sacroiliitis in first-degree relatives of patients with ankylosing spondylitis (AS) and to determine fulfilment of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial and/or peripheral spondyloarthritis (SpA), and the clinical diagnosis of SpA.

Methods: One hundred subjects without a previous rheumatological diagnosis with a first-degree relative treated for AS were included in the study. Clinical data were collected and rheumatological examinations were performed by trained rheumatologists. Magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) was read by a trained rheumatologist who was blinded to all patient data. Subjects were further divided into both SpA (according to ASAS classification criteria and clinician opinion) and non-SpA subgroups.

Results: We detected active sacroiliitis defined by MRI in 13 subjects who were further diagnosed with axSpA, 7 (54%) of whom already had advanced radiographic changes on conventional radiographs of the sacroiliac joints. In addition, active sacroiliitis was also present in 4 individuals who did not have back pain. The data are shown in Figure 1. A total of 26 subjects met ASAS classification criteria for SpA, of which the diagnosis of SpA was confirmed in 14 subjects (13 subjects met ASAS classification criteria for axial and 1 subject for peripheral SpA). In addition, 12 individuals met the clinical arm of the ASAS classification criteria for axSpA, but were not diagnosed with axSpA in the clinicians’ opinion. Analysis of clinical characteristics showed a significant difference in CRP and BASDAI between the SpA vs. non-SpA subgroups (8.8 (±10.5) vs. 2.3 (±4.1) mg/l, p=0.0048, and 3.1 (±1.8) vs. 1.76 (±1.78), respectively). Individuals diagnosed with SpA were more likely to be HLA-B27 positive and had inflammatory back pain compared to the non-SpA subgroup (87% vs. 43%, p=0.0069 and 57% vs. 9%, p=0.0002, respectively). Individuals who were not diagnosed with SpA but met the clinical arm of the ASAS classification criteria for axSpA were excluded from the analysis. Other clinical characteristics and differences between subgroups are shown in Table 1.

Conclusion: In this cross-sectional study, 17% of first degree relatives of patients with AS had MRI- defined sacroiliitis, however not all of them were diagnosed with SpA due to the absence of back pain. A quarter of the subjects with first-degree AS relative met the classification criteria for SpA, and 14% were diagnosed with SpA based on physician opinion.

Supporting image 1

Distribution of the first degree relatives according to the diagnosis of spondyloarthritis

Supporting image 2

Patient characteristics and subsets differences


Disclosures: K. Bubova: None; L. Hasikova: None; K. Mintalova: None; M. Gregova: None; S. Forejtova: None; L. Senolt: None; K. Pavelka: Abbvie, 2, 6, Amgen, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Egis, 2, 6, MSD, 2, 6, Pfizer, 2, 6, Roche, 2, 6, UCB, 2, 6.

To cite this abstract in AMA style:

Bubova K, Hasikova L, Mintalova K, Gregova M, Forejtova S, Senolt L, Pavelka K. MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mri-defined-sacroiliitis-in-first-degree-relatives-of-ankylosing-spondylitis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mri-defined-sacroiliitis-in-first-degree-relatives-of-ankylosing-spondylitis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology